Related Experiment Videos
[Ki67 in young patients with breast cancer]
F Vasseur1, M-C Baranzelli, C Fournier
1Département de sénologie, centre Oscar-Lambret, 3 rue Fréderic-Combemale, Lille, France.
Insights
Young breast cancer patients exhibit significantly higher KI67 levels and a greater prevalence of triple-negative breast cancer (TNBC). In young patients, TNBC is associated with even higher KI67 expression, indicating aggressive tumor biology.
Area of Science:
- Oncology
- Pathology
- Biomarkers
Background:
- Younger breast cancer patients (≤35 years) often present with more aggressive disease compared to older patients.
- Understanding specific biomarker profiles in young breast cancer is crucial for tailored treatment strategies.
Purpose of the Study:
- To compare KI67 levels and other key biomarkers between young (≤35 years) and older breast cancer patients.
- To investigate the prevalence and characteristics of triple-negative breast cancer (TNBC) in these age groups.
Main Methods:
- Retrospective analysis of 43 young breast cancer patients (diagnosed 2006-2008) and older patients (diagnosed 2006).
- Biomarker analysis (KI67, ER, PR, HER2) performed on surgical specimens or pre-neoadjuvant chemotherapy biopsies.
- Statistical comparison of biomarker expression, tumor grade, and TNBC rates between age groups.
Main Results:
- Young patients showed significantly higher median KI67 (30% vs. 10%, P<0.0001) and a higher rate of SBR Grade 3 (44% vs. 28%, P<0.04).
- Estrogen Receptor (ER) and Progesterone Receptor (PR) positivity were less frequent in young patients (ER: 56% vs. 87%, P<0.001; PR: 38% vs. 68%, P<0.001).
- HER2 amplification (24% vs. 10%, P<0.007) and triple-negative breast cancer (TNBC) (31% vs. 8%, P<0.001) were significantly more common in young patients.
Conclusions:
- KI67 is significantly elevated in young breast cancer patients compared to older counterparts.
- TNBC is more prevalent in younger patients, and within this group, TNBC exhibits higher KI67 expression, suggesting more aggressive tumor behavior.
Unlabelled:
The aim of the study was to compare KI67 in young breast cancer patients (pts) (35 years or less), and in older ones. Forty-three young pts treated between January 1, 2006 and December 31, 2008 as well as pts more than 35 years treated in the same institution in 2006 were considered. Biomarker studies were carried out on a surgical specimen or on a biopsy before neoadjuvant chemotherapy if any. Young pts had a higher median value of KI67 (30% [3-95] versus 10% [0-90] P<0.0001) a higher rate of SBR3 (44 versus 28% P<04), of mitotic index 3 (35 versus 13% P<0.001). ER was less frequently positive (56 versus 87%, P<0.001) as well as PR (38 versus 68% P<0.001). HER2 was more frequently amplified in young pts (24 versus 10% P<0.007). Young pts more frequently had a triple negative breast cancer (TNBC) (31 versus 8% P<0.001). In TNBC pts, KI67 was higher in younger pts (70% [10-95] versus 38% [2-80] P=0.06). Among young pts, TNBC had a higher KI67 than non TNBC (70% [10-95 versus 20% [3-60] P<0.001).
Conclusion:
KI67 is significantly higher in young pts than in older ones. TNBC is significantly more frequent; among young pts, and KI67 is significantly higher in TNBC.
